메뉴 건너뛰기




Volumn 35, Issue 6, 2017, Pages 605-612

Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial

(45)  Platzbecker, Uwe a,b   Avvisati, Giuseppe o   Cicconi, Laura p   Thiede, Christian a   Paoloni, Francesca q   Vignetti, Marco q,r   Ferrara, Felicetto s   Divona, Mariadomenica p   Albano, Francesco t   Efficace, Fabio q   Fazi, Paola q   Sborgia, Marco u   Di Bona, Eros v   Breccia, Massimo r   Borlenghi, Erika w   Cairoli, Roberto x   Rambaldi, Alessandro z   Melillo, Lorella aa   La Nasa, Giorgio ab   Fiedler, Walter c   more..


Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; RETINOIC ACID; ORGANOARSENIC DERIVATIVE; OXIDE;

EID: 85013070481     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.1982     Document Type: Article
Times cited : (300)

References (26)
  • 1
    • 0037115195 scopus 로고    scopus 로고
    • All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol
    • Tallman MS, Andersen JW, Schiffer CA, et al: All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100:4298-4302, 2002
    • (2002) Blood , vol.100 , pp. 4298-4302
    • Tallman, M.S.1    Andersen, J.W.2    Schiffer, C.A.3
  • 2
    • 34347386848 scopus 로고    scopus 로고
    • A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study
    • Asou N, Kishimoto Y, Kiyoi H, et al: A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood 110:59-66, 2007
    • (2007) Blood , vol.110 , pp. 59-66
    • Asou, N.1    Kishimoto, Y.2    Kiyoi, H.3
  • 3
    • 74049115852 scopus 로고    scopus 로고
    • High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG
    • Lengfelder E, Haferlach C, Saussele S, et al: High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG. Leukemia 23:2248-2258, 2009
    • (2009) Leukemia , vol.23 , pp. 2248-2258
    • Lengfelder, E.1    Haferlach, C.2    Saussele, S.3
  • 4
    • 77950361899 scopus 로고    scopus 로고
    • Very longterm outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience
    • Adès L, Guerci A, Raffoux E, et al: Very longterm outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: The European APL Group experience. Blood 115:1690-1696, 2010
    • (2010) Blood , vol.115 , pp. 1690-1696
    • Adès, L.1    Guerci, A.2    Raffoux, E.3
  • 5
    • 77954681398 scopus 로고    scopus 로고
    • Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome
    • Sanz MA, Montesinos P, Rayón C, et al: Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome. Blood 115:5137-5146, 2010
    • (2010) Blood , vol.115 , pp. 5137-5146
    • Sanz, M.A.1    Montesinos, P.2    Rayón, C.3
  • 6
    • 79955991053 scopus 로고    scopus 로고
    • AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: Very long-term results and role of maintenance
    • Avvisati G, Lo-Coco F, Paoloni FP, et al: AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: Very long-term results and role of maintenance. Blood 117:4716-4725, 2011
    • (2011) Blood , vol.117 , pp. 4716-4725
    • Avvisati, G.1    Lo-Coco, F.2    Paoloni, F.P.3
  • 7
    • 84856501661 scopus 로고    scopus 로고
    • Results of the APML3 trial incorporating all-transretinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
    • Iland H, Bradstock K, Seymour J, et al: Results of the APML3 trial incorporating all-transretinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 97:227-234, 2012
    • (2012) Haematologica , vol.97 , pp. 227-234
    • Iland, H.1    Bradstock, K.2    Seymour, J.3
  • 8
    • 84876120195 scopus 로고    scopus 로고
    • Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: Results of the MRC AML15 trial
    • Burnett AK, Hills RK, Grimwade D, et al: Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: Results of the MRC AML15 trial. Leukemia 27:843-851, 2013
    • (2013) Leukemia , vol.27 , pp. 843-851
    • Burnett, A.K.1    Hills, R.K.2    Grimwade, D.3
  • 9
    • 61949441174 scopus 로고    scopus 로고
    • Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet
    • Sanz MA, Grimwade D, Tallman MS, et al: Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875-1891, 2009
    • (2009) Blood , vol.113 , pp. 1875-1891
    • Sanz, M.A.1    Grimwade, D.2    Tallman, M.S.3
  • 10
    • 41949111045 scopus 로고    scopus 로고
    • Acute promyelocytic leukemia: From highly fatal to highly curable
    • Wang ZY, Chen Z: Acute promyelocytic leukemia: From highly fatal to highly curable. Blood 111:2505-2515, 2008
    • (2008) Blood , vol.111 , pp. 2505-2515
    • Wang, Z.Y.1    Chen, Z.2
  • 11
    • 77956249684 scopus 로고    scopus 로고
    • Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline-based chemotherapy
    • Montesinos P, González JD, González J, et al: Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-transretinoic acid and anthracycline-based chemotherapy. J Clin Oncol 28:3872-3879, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 3872-3879
    • Montesinos, P.1    González, J.D.2    González, J.3
  • 12
    • 84865074686 scopus 로고    scopus 로고
    • The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies
    • de Thé H, Le Bras M, Lallemand-Breitenbach V: The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol 198:11-21, 2012
    • (2012) J Cell Biol , vol.198 , pp. 11-21
    • De Thé, H.1    Le Bras, M.2    Lallemand-Breitenbach, V.3
  • 13
    • 84878562951 scopus 로고    scopus 로고
    • Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide
    • Mathews V, Chendamarai E, George B, et al: Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis 3:e2011056, 2011
    • (2011) Mediterr J Hematol Infect Dis , vol.3
    • Mathews, V.1    Chendamarai, E.2    George, B.3
  • 14
    • 84860111877 scopus 로고    scopus 로고
    • Arsenic trioxide for management of acute promyelocytic leukemia: Current evidence on its role in front-line therapy and recurrent disease
    • Breccia M, Lo-Coco F: Arsenic trioxide for management of acute promyelocytic leukemia: Current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother 13:1031-1043, 2012
    • (2012) Expert Opin Pharmacother , vol.13 , pp. 1031-1043
    • Breccia, M.1    Lo-Coco, F.2
  • 15
    • 0000531696 scopus 로고    scopus 로고
    • Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
    • Shao W, Fanelli M, Ferrara FF, et al: Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90:124-133, 1998
    • (1998) J Natl Cancer Inst , vol.90 , pp. 124-133
    • Shao, W.1    Fanelli, M.2    Ferrara, F.F.3
  • 16
    • 79960225126 scopus 로고    scopus 로고
    • Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia
    • Ghavamzadeh A, Alimoghaddam K, Rostami S, et al: Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29:2753-2757, 2011
    • (2011) J Clin Oncol , vol.29 , pp. 2753-2757
    • Ghavamzadeh, A.1    Alimoghaddam, K.2    Rostami, S.3
  • 17
    • 33645498328 scopus 로고    scopus 로고
    • Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity
    • Mathews V, George B, Lakshmi KM, et al: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107:2627-2632, 2006
    • (2006) Blood , vol.107 , pp. 2627-2632
    • Mathews, V.1    George, B.2    Lakshmi, K.M.3
  • 18
    • 33646386643 scopus 로고    scopus 로고
    • Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    • Estey E, Garcia-Manero G, Ferrajoli A, et al: Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 107:3469-3473, 2006
    • (2006) Blood , vol.107 , pp. 3469-3473
    • Estey, E.1    Garcia-Manero, G.2    Ferrajoli, A.3
  • 19
    • 59149089411 scopus 로고    scopus 로고
    • Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    • Ravandi F, Estey E, Jones D, et al: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 27:504-510, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 504-510
    • Ravandi, F.1    Estey, E.2    Jones, D.3
  • 20
    • 84880287051 scopus 로고    scopus 로고
    • Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
    • Lo-Coco F, Avvisati G, Vignetti M, et al: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111-121, 2013
    • (2013) N Engl J Med , vol.369 , pp. 111-121
    • Lo-Coco, F.1    Avvisati, G.2    Vignetti, M.3
  • 21
    • 84948978098 scopus 로고    scopus 로고
    • Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial
    • Burnett AK, Russell NH, Hills RK, et al: Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): Results of a randomised, controlled, phase 3 trial. Lancet Oncol 16:1295-1305, 2015
    • (2015) Lancet Oncol , vol.16 , pp. 1295-1305
    • Burnett, A.K.1    Russell, N.H.2    Hills, R.K.3
  • 23
    • 84907806243 scopus 로고    scopus 로고
    • A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults
    • Seftel MD, Barnett MJ, Couban S, et al.: A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults. Curr Oncol 21:234-250, 2014
    • (2014) Curr Oncol , vol.21 , pp. 234-250
    • Seftel, M.D.1    Barnett, M.J.2    Couban, S.3
  • 24
    • 59649106888 scopus 로고    scopus 로고
    • Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
    • Montesinos P, Bergua JM, Vellenga E, et al: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors. Blood 113:775-783, 2009
    • (2009) Blood , vol.113 , pp. 775-783
    • Montesinos, P.1    Bergua, J.M.2    Vellenga, E.3
  • 25
    • 0026647140 scopus 로고
    • The "retinoic acid syndrome" in acute promyelocytic leukemia
    • Frankel SR, Eardley A, Lauwers G, et al: The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117:292-296, 1992
    • (1992) Ann Intern Med , vol.117 , pp. 292-296
    • Frankel, S.R.1    Eardley, A.2    Lauwers, G.3
  • 26
    • 84908406763 scopus 로고    scopus 로고
    • Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes
    • Efficace F, Mandelli F, Avvisati G, et al: Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes. J Clin Oncol 32:3406-3412, 2014
    • (2014) J Clin Oncol , vol.32 , pp. 3406-3412
    • Efficace, F.1    Mandelli, F.2    Avvisati, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.